GE HealthCare stock heads into the open after a 0.9% dip
Published on 09/18/2026 at 07:24 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
GE HealthCare stock closed at USD 63.49 on the Nasdaq on September 16, 2026, down 0.91% from the previous session. The shares traded in a relatively narrow band that day while major US indices advanced, leaving the stock lagging the broader market.
September 16, 2026 in numbers
GE HealthCare Technologies Inc. (ISIN US36266G1076, Nasdaq: GEHC) ended the September 16, 2026 session at USD 63.49 on Nasdaq after moving between an intraday high of USD 64.46 and a low of USD 63.28, with trading volume around 3.22 million shares per Investing.com data for that date. Compared with its prior close, the stock slipped 0.91% on the day, even as US benchmarks such as the S&P 500 posted gains, underscoring relative weakness in the name during that session. Over the 08/17/2026 to 09/17/2026 period shown in the same Investing.com quote history, the September 16 close of USD 63.49 was toward the lower end of its recent trading range, consistent with year-to-date softness highlighted in analyst commentary.
On September 17, 2026, BTIG reiterated a Buy rating and maintained a USD 79.00 price target on GE HealthCare, citing positive feedback for the company’s next-generation photon-counting CT system and a solid imaging order backdrop, as reported by Investing.com. That note framed the September 16, 2026 close of USD 63.49 as roughly 22% below the level at the start of 2026 and about 24% below BTIG’s target, underlining how recent price weakness contrasts with the broker’s constructive medium-term view. In parallel, GE HealthCare announced on September 17, 2026 that its Photonova Spectra photon-counting CT system received CE Mark approval, enabling commercial activities in European markets that recognize the certification, according to Endovascular Today; together, the analyst support and regulatory milestone formed a key backdrop to the prior session’s trading profile.
Today’s factors for GE HealthCare
Looking ahead to today’s US open on September 18, 2026, investors in GE HealthCare are likely to weigh the fresh CE Mark approval for Photonova Spectra and BTIG’s reaffirmed Buy rating as potential sentiment drivers, even though both were published after the September 16, 2026 close. The CE Mark announcement confirms that GE HealthCare is starting commercial activities for Photonova Spectra in countries that observe the certification, a step that could influence expectations for imaging-system revenue over time, as detailed by Endovascular Today. At the same time, BTIG’s September 17, 2026 note positions GE HealthCare shares among the more undervalued names in the healthcare equipment group based on InvestingPro-style analysis and reiterates a USD 79.00 target, according to Investing.com, which may shape how the market interprets the stock’s discount to that level going into today’s session. Broader US equity conditions also enter the picture: technology and growth-oriented shares led a rebound on September 17, 2026 as oil prices eased and Treasury yields dipped, with the S&P 500 rising 1.14% and the Nasdaq Composite gaining 1.69%, according to a wrap by The Straits Times, a backdrop that could influence risk appetite for healthcare equipment names such as GE HealthCare today.
